Abdi SAH, Shukla S, Khan J, Al Zahrani A, et al. Hepatotoxicity is the risk factor with gemtuzumab ozogamicin treatment in acute myelogenous leukaemia patients. Clin Res Hepatol Gastroenterol 2021;45:101443.
PMID: 32448587